Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities (ITT)
Prospective Randomised Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities
Sponsor: Kimberly-Clark Corporation
Terminated
Interim analyses showed insufficient result. Termination for reasons of futility
Listed as NCT00940979, this NA trial focuses on Arterial Obstructive Diseases and remains terminated or withdrawn. Sponsored by Kimberly-Clark Corporation, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Jan 2026 — Present [monthly]
Terminated NA
-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Jan 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kimberly-Clark Corporation
- Rijnstate Hospital
For direct contact, visit the study record on ClinicalTrials.gov .